Vaginal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Vaginal cancer is rare cancer that occurs in the vagina. Its symptoms include watery vaginal discharge, a lump or mass in the vagina, painful urination, constipation, and pelvic pain, vaginal bleeding.
The Vaginal Cancer pipeline market research report provides comprehensive information on the therapeutics under development for Vaginal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vaginal Cancer and features dormant and discontinued projects.
Vaginal Cancer Pipeline Products Market Segmentation by Targets
The key targets in the Vaginal Cancer pipeline products market are Human Papillomavirus Protein E6, Human Papillomavirus Protein E7, Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Cytotoxic T Lymphocyte Protein 4, Cells Expressing Human Papillomavirus Protein E7, Human Papillomavirus Major Capsid Protein L1, Transforming Growth Factor Beta, Cadherin 3, Cells Expressing Human Papillomavirus Protein E6, and others.
Vaginal Cancer Pipeline Products Market Analysis by Targets
For more target insights into the Vaginal Cancer pipeline products market, download a free report sample
Vaginal Cancer Pipeline Products Market Segmentation by Mechanisms of Action
The key mechanisms of action in the Vaginal Cancer pipeline products market are Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Cytotoxic To Cells Expressing Human Papillomavirus Protein E7, Transforming Growth Factor Beta Inhibitor, Cadherin 3 Inhibitor, Cytotoxic To Cells Expressing Human Papillomavirus Protein E6, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, DNA (Cytosine 5) Methyltransferase 1 Inhibitor, DNA Synthesis Inhibitor, and others.
Vaginal Cancer Pipeline Products Market Analysis by Mechanisms of Action
For more mechanisms of action insights into the Vaginal Cancer pipeline products market, download a free report sample
Vaginal Cancer Pipeline Products Market Segmentation by Routes of Administration
The key routes of administration in the Vaginal Cancer pipeline products market are intravenous, intramuscular, subcutaneous, intraperitoneal, oral, intratumor, intravenous drip, intravesical, parenteral, and others.
Vaginal Cancer Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights into the Vaginal Cancer pipeline products market, download a free report sample
Vaginal Cancer Pipeline Products Market Segmentation by Molecule Types
The key molecule types in the Vaginal Cancer pipeline products market are monoclonal antibody, subunit vaccine, small molecule, recombinant vector vaccine, cell therapy, fusion protein, monoclonal antibody conjugated, DNA vaccine, gene-modified cell therapy, oncolytic virus, and vaccine.
Vaginal Cancer Pipeline Products Market Analysis by Molecule Types
For more molecule type insights into the Vaginal Cancer pipeline products market, download a free report sample
Vaginal Cancer Pipeline Products Market - Competitive Landscape
Some of the leading companies in the Vaginal Cancer pipeline products market are AstraZeneca Plc, Merck & Co Inc, Bristol-Myers Squibb Co, Hookipa Pharma Inc, Merck KGaA, Pionyr Immunotherapeutics Inc, Privo Technologies Inc, Shanghai Bovax Biotechnology Co Ltd, SQZ Biotechnologies Co, and Beijing Kangle Guardian Biotechnology Co Ltd.
Vaginal Cancer Pipeline Products Market Analysis by Companies
To know more about the leading players in the Vaginal Cancer pipeline products market, download a free report sample
Vaginal Cancer Pipeline Products Market Report Overview
Key Targets | Human Papillomavirus Protein E6, Human Papillomavirus Protein E7, Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Cytotoxic T Lymphocyte Protein 4, Cells Expressing Human Papillomavirus Protein E7, Human Papillomavirus Major Capsid Protein L1, Transforming Growth Factor Beta, Cadherin 3, Cells Expressing Human Papillomavirus Protein E6, and Others |
Key Mechanisms of Action | Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Cytotoxic To Cells Expressing Human Papillomavirus Protein E7, Transforming Growth Factor Beta Inhibitor, Cadherin 3 Inhibitor, Cytotoxic To Cells Expressing Human Papillomavirus Protein E6, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, DNA (Cytosine 5) Methyltransferase 1 Inhibitor, DNA Synthesis Inhibitor, and Others |
Key Routes of Administration | Intravenous, Intramuscular, Subcutaneous, Intraperitoneal, Oral, Intratumor, Intravenous Drip, Intravesical, Parenteral, and Others |
Key Molecule Type | Monoclonal Antibody, Subunit Vaccine, Small Molecule, Recombinant Vector Vaccine, Cell Therapy, Fusion Protein, Monoclonal Antibody Conjugated, DNA Vaccine, Gene-Modified Cell Therapy, Oncolytic Virus, and Vaccine |
Leading Companies | AstraZeneca Plc, Merck & Co Inc, Bristol-Myers Squibb Co, Hookipa Pharma Inc, Merck KGaA, Pionyr Immunotherapeutics Inc, Privo Technologies Inc, Shanghai Bovax Biotechnology Co Ltd, SQZ Biotechnologies Co, and Beijing Kangle Guardian Biotechnology Co Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Vaginal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Vaginal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Vaginal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Vaginal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Vaginal Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Vaginal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Vaginal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Beijing Kangle Guardian Biotechnology Co Ltd
Beijing Kangleweishi Biotechnology Co Ltd
Bristol-Myers Squibb Co
Chengdu Institute of Biological Products Co Ltd
Eisai Co Ltd
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
Hookipa Pharma Inc
ISA Pharmaceuticals BV
Merck & Co Inc
Merck KGaA
Ology Bioservices Inc
Ono Pharmaceutical Co Ltd
PDS Biotechnology Corp
Perseus Proteomics Inc
Pionyr Immunotherapeutics Inc
Precigen Inc
Privo Technologies Inc
RemeGen Co Ltd
Shanghai Bovax Biotechnology Co Ltd
Shanghai Zerun Biotechnology Co Ltd
SinoCelltech Group Ltd
SQZ Biotechnologies Co
Suzhou Neupharma Co Ltd
Transcenta Holding Ltd
Transgene SA
Turnstone Biologics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Vaginal Cancer pipeline products market?
The key targets in the Vaginal Cancer pipeline products market are Human Papillomavirus Protein E6, Human Papillomavirus Protein E7, Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Cytotoxic T Lymphocyte Protein 4, Cells Expressing Human Papillomavirus Protein E7, Human Papillomavirus Major Capsid Protein L1, Transforming Growth Factor Beta, Cadherin 3, Cells Expressing Human Papillomavirus Protein E6, and others.
-
What are the key mechanisms of action in the Vaginal Cancer pipeline products market?
The key mechanisms of action in the Vaginal Cancer pipeline products market are Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Cytotoxic To Cells Expressing Human Papillomavirus Protein E7, Transforming Growth Factor Beta Inhibitor, Cadherin 3 Inhibitor, Cytotoxic To Cells Expressing Human Papillomavirus Protein E6, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, DNA (Cytosine 5) Methyltransferase 1 Inhibitor, DNA Synthesis Inhibitor, and others.
-
What are the key routes of administration in the Vaginal Cancer pipeline products market?
The key routes of administration in the Vaginal Cancer pipeline products market are intravenous, intramuscular, subcutaneous, intraperitoneal, oral, intratumor, intravenous drip, intravesical, parenteral, and others.
-
What are the key molecule types in the Vaginal Cancer pipeline products market?
The key molecule types in the Vaginal Cancer pipeline products market are monoclonal antibody, subunit vaccine, small molecule, recombinant vector vaccine, cell therapy, fusion protein, monoclonal antibody conjugated, DNA vaccine, gene-modified cell therapy, oncolytic virus, and vaccine.
-
Which are the leading companies in the Vaginal Cancer pipeline products market?
Some of the leading companies in the Vaginal Cancer pipeline products market are AstraZeneca Plc, Merck & Co Inc, Bristol-Myers Squibb Co, Hookipa Pharma Inc, Merck KGaA, Pionyr Immunotherapeutics Inc, Privo Technologies Inc, Shanghai Bovax Biotechnology Co Ltd, SQZ Biotechnologies Co, and Beijing Kangle Guardian Biotechnology Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.